BioCentury
ARTICLE | Product R&D

Tempest takes PPAR alpha into cancer

Why Tempest thinks PPARα could succeed in cancer where IDO failed

November 15, 2018 10:55 PM UTC

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer.

Tapping into the emerging field of cancer immuno-metabolism, Tempest is moving beyond IDO with a target that acts via a different mechanism and controls cancer cells in addition to immune cells. ...